NTM

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Votes for All WisdomTree Proposals, Including Votes for All Nine WisdomTree Board Nominees and Reiterates Company’s “Compelling” Strategic Vision

Retrieved on: 
金曜日, 5月 31, 2024
Consulting, Banking, Professional Services, Finance, BofA Securities, Internet, Decentralized finance, CARD, Peer group, EPS, BlackRock, NTM, Cryptocurrency

Win Neuger, Chair of the WisdomTree Board of Directors, said, “We are pleased that Glass Lewis recognizes the value WisdomTree continues to deliver to its stockholders.

Key Points: 
  • Win Neuger, Chair of the WisdomTree Board of Directors, said, “We are pleased that Glass Lewis recognizes the value WisdomTree continues to deliver to its stockholders.
  • Glass Lewis has made an independent assessment and concluded that there is no case for change at WisdomTree.
  • PLEASE VOTE THE WHITE PROXY CARD TODAY “FOR” ALL WISDOMTREE NOMINEES!
  • Innisfree M&A is serving as proxy solicitor, and H/Advisors Abernathy is serving as strategic communications advisor.

MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix

Retrieved on: 
水曜日, 5月 29, 2024
Patient, Technosphere, Dihydroergotamine, Research and development, DHE, FDA, Migraine, Doctor of Pharmacy, DSM-IV codes, Cricket, Professional corporation, Idiopathic pulmonary fibrosis, Insulin, MannKind Corporation, Pulmonary fibrosis, NTM, IPF, ILD, PFF, Development, Pharmaceutical industry

The two companies also agreed that Pulmatrix will transfer its Bedford, Mass.

Key Points: 
  • The two companies also agreed that Pulmatrix will transfer its Bedford, Mass.
  • R&D facility to MannKind, along with all leasehold improvements, laboratory equipment and other related personal property used in the laboratory in non-cash transaction.
  • MannKind expects to consolidate its Boston presence by transitioning its Marlborough staff into the newly renovated, fully outfitted R&D facility in Bedford.
  • To maintain continuity of iSPERSE platform knowledge, MannKind plans to hire some members of current Pulmatrix R&D staff.

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

Retrieved on: 
水曜日, 5月 15, 2024
FDA, GSK, Fast Track, NTM, Unitary state, Research, G&A, Bangladesh Technical Education Board, NIAID, Infection, AP, Pseudomonas aeruginosa, Acinetobacter baumannii, Army, Human services, Urinary tract infection, Clinical trial, National Institutes of Health, Safety, MDR, Pyelonephritis, Administration, Department of Defence, Policy, Mycobacterium avium complex, Patient, Pharmacokinetics, Therapy, Assistant, HBR, Tebipenem, Federal, Government, Quality of life, Pharmaceutical industry

Supported by a strong balance sheet, Spero remains well capitalized with expected cash runway into late 2025.”

Key Points: 
  • Supported by a strong balance sheet, Spero remains well capitalized with expected cash runway into late 2025.”
    Top-line data from the Phase 2a proof-of-concept clinical trial are expected in 2H 2024.
  • Total revenue for the first quarter of 2024 was $9.3 million, compared with total revenue of $2.1 million for the first quarter of 2023.
  • General and administrative expenses for the first quarter of 2024 were $5.9 million, compared to $7.3 million for the same period in 2023.
  • As of March 31, 2024, Spero had cash and cash equivalents of $82.3 million, compared to $76.3 million at December 31, 2023.

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Retrieved on: 
火曜日, 5月 14, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Insurance, Patient, Infection, MAC, Investment, Clinical trial, FDA, Therapy, Safety, IPO, AN2, Incidence, NTM, Research and development, Administration, Nontuberculous mycobacteria, Entrepreneurship, Phase II, Pharmaceutical industry

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024.

Key Points: 
  • AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024.
  • “We hope to see data demonstrating that epetraborole on top of background therapy will show benefit in these toughest to treat patients.
  • Net loss: Net loss for the first quarter of 2024 was $16.6 million, compared to $15.3 million for the same period during 2023.
  • Cash Position: The Company had cash, cash equivalents, and investments of $118.1 million at March 31, 2024.

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Retrieved on: 
月曜日, 5月 6, 2024
FDA, QIDP, Fast Track, Safety, Infection, Woman, Food, Prevalence, Bacteria, Cough, Water, NTM, Environment, MAC, Patient, Doctor of Pharmacy, Fatigue, Bronchiectasis, Medicine, Soil, MannKind Corporation, Mycobacterium avium complex, Asthma, COPD, Pharmaceutical industry

Fast track designation is intended to facilitate the development, and expedite the review, of medicines to treat serious conditions and fill an unmet medical need.

Key Points: 
  • Fast track designation is intended to facilitate the development, and expedite the review, of medicines to treat serious conditions and fill an unmet medical need.
  • “We are pleased with the FDA’s decision to grant Fast Track designation for Clofazimine Inhalation Suspension, providing us an opportunity to accelerate our efforts to potentially bring an important medicine to patients living with NTM,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation.
  • The U.S. FDA previously designated Clofazimine Inhalation Suspension as both an orphan drug and a qualified infectious disease product (QIDP) for the treatment of pulmonary NTM infections.
  • NTM lung disease is more common in women over the age of 65, with a predominance in those of Caucasian and Asian descent.

CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference

Retrieved on: 
木曜日, 4月 11, 2024
Mortality, Society, Gram-positive bacteria, Economics, Abstract, Bacteria, NTM, BSI, Patient, Gram-negative bacteria, CVC

BERKELEY HEIGHTS, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that two abstracts have been accepted for presentation at the Society for Healthcare Epidemiology of America (SHEA) conference being held in Houston, Texas, April 16 – 19, 2024.

Key Points: 
  • BERKELEY HEIGHTS, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that two abstracts have been accepted for presentation at the Society for Healthcare Epidemiology of America (SHEA) conference being held in Houston, Texas, April 16 – 19, 2024.
  • The first abstract being presented examines in vitro antimicrobial activity of taurolidine against a set of recent clinical isolates representative of bacteria recovered from the LOCK-IT 100 trial and those commonly associated with CRBSI.
  • Based on these data, taurolidine demonstrated broad antimicrobial activity against all gram-positive bacteria, including non-tuberculosis Mycobacteria (NTM), gram-negative bacteria, and fungal isolates tested.
  • In addition, the activity of taurolidine was unaffected by resistance to common antibiotics.

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Retrieved on: 
水曜日, 3月 13, 2024
Gram-negative bacteria, Department of Defence, Urinary tract infection, GSK, Patient, Human services, Quality of life, IND, Tebipenem, Clinical trial, Therapy, Infection, Research, Policy, Treasurer, Carbapenem-resistant enterobacteriaceae, Safety, Pharmacokinetics, Federal, Food, AP, Drug discovery, Disease, Kidney, SPA, Acinetobacter baumannii, MDR, Pyelonephritis, Annual report, FDA, Army, HBR, Government, Unitary state, NTM, Assistant, Fungal infection, Pseudomonas aeruginosa, Hope, National Institutes of Health, ID, Mycobacterium avium complex, Bangladesh Technical Education Board, Administration, Pharmaceutical industry

“2023 was a productive year for Spero and we have been focused on execution across our programs,” said Sath Shukla, President, and Chief Executive Officer of Spero.

Key Points: 
  • “2023 was a productive year for Spero and we have been focused on execution across our programs,” said Sath Shukla, President, and Chief Executive Officer of Spero.
  • Top-line data from the Phase 2a proof-of-concept clinical trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients is expected in 2H 2024.
  • Spero commenced enrollment in PIVOT-PO, a global, randomized, double-blind, Phase 3 clinical trial of tebipenem HBr in patients with cUTI, including AP in December 2023.
  • Total revenue for the fourth quarter of 2023 was $73.5 million, compared with total revenue of $47.4 million for the fourth quarter of 2022.

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Retrieved on: 
木曜日, 3月 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious Diseases, Clinical Trials, Administration, Nontuberculous mycobacteria, Conference, Bill, AN2, Entrepreneurship, NTM, Boron, Tuberculosis, University, Patient, Melioidosis, Data monitoring committee, G&A, MAC, Insurance, Infection, Wellcome Trust, Investment, Clinical trial, Chagas disease, Therapy, Malaria, Safety, Poster, Research and development, Mycobacteroides abscessus, IDSA, Trust, Pharmaceutical industry

Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer.

Key Points: 
  • Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer.
  • Net loss: Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year.
  • Net loss for the fourth quarter of 2023 was $16.9 million, compared to $11.8 million for the same period during 2022.
  • Cash Position: The Company had cash, cash equivalents, and investments of $134.5 million at December 31, 2023.

Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer

Retrieved on: 
木曜日, 3月 7, 2024
Rochester University, Bronchiectasis, Roche, Cystic fibrosis, MD, NIH, Medical director, Nephrotoxicity, Astellas Pharma, MBA, TB, ARUP Laboratories, University of Utah, University, Therapy, Pathology, TB Alliance, Associate, Patient, Duke University, Diagnosis, Tuberculosis, Pseudomonas aeruginosa, NTM, Publication, IND, Pharmaceutical industry

MORRISVILLE, N.C., March 7, 2024 /PRNewswire/ -- Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer. Dr. Bruinenberg brings over 30 years of experience as a clinical development executive in respiratory medicine and orphan diseases. This appointment and the recent addition of microbiologist and clinical diagnostics expert Chris Polage, MD, as Medical Director, significantly bolster the company's clinical development expertise in pulmonary infectious diseases and medical microbiology. 

Key Points: 
  • MORRISVILLE, N.C., March 7, 2024 /PRNewswire/ -- Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer.
  • "Paul's development experience will guide Vast Therapeutics as we successfully transition to a clinical-stage organization," said Nate Stasko, Chief Executive Officer at Vast Therapeutics.
  • "It is an amazing opportunity to join a company with an accepted IND for a novel treatment modality that shows promising efficacy against chronic infections caused by Pseudomonas aeruginosa and non-tuberculosis mycobacteria," commented Paul Bruinenberg, Chief Medical Officer at Vast Therapeutics.
  • Most recently, Dr. Bruinenberg served as the Senior Medical Officer of the TB Alliance leading clinical development against mycobacterial infections.

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024

Retrieved on: 
月曜日, 2月 12, 2024
Nitrogen oxide, Conference call, Nitric oxide, Research, PMA, B cell, Hebrew University of Jerusalem, FDA, Clinical research associate, SITC, NOS1, UNO, Pneumonia, Season, ASD, Society, Conference, Commercial, HUJI, Phenotype, Patient, DSM-IV codes, Immunotherapy, VCAP, NTM, Fiscal year, Nontuberculous mycobacteria

“In the third quarter of fiscal year 2024, we reported solid sequential revenue growth of more than 60% compared with the second quarter.

Key Points: 
  • “In the third quarter of fiscal year 2024, we reported solid sequential revenue growth of more than 60% compared with the second quarter.
  • This increasing demand for our current LungFit PH system was seen even as we prepared to launch a key software update.
  • As our inventory of upgraded LungFit PH grows, we expect to be able to meet accelerating demand over the next several quarters.
  • General and administrative expenses for the three months ended December 31, 2023 and December 31, 2022 were $9.8 million and $8.9 million, respectively.